The US Zolgensma Review: Full Speed Ahead Despite Dose, Stability, Method Uncertainties
Executive Summary
Normally, toddlers with infantile-onset spinal muscular atrophy would be in bed on ventilators. But most of these were sitting up on their own. Two were even standing and walking. The question was how to get the manufacturing process for the gene therapy that worked this magic ready for prime time.
You may also be interested in...
Keeping Track: Novartis Scores Big Ahead Of US Memorial Day With Approvals For Gene Therapy Zolgensma, Oncologic Piqray
The latest drug development news and highlights from our US FDA Performance Tracker.
Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition
The Swiss major has made a larger-than-expected bolt-on buy, using a large chunk of its $13bn windfall from GSK to get hold of a potential cure for spinal muscular atrophy and an additional gene therapy platform, as well as manufacturing capabilities.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.